ImmunoCellular Therapeutics, Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, net loss was $1,024,981 against $5,927,763 a year ago. Net loss per share, basic and diluted was $0.02 against $1.67 a year ago. The company reported $1.6 million of cash used in operations during the most recent quarter compared to $6.1 million in the same period in 2017. The decrease in the net loss is primarily due to the suspension of the ICT-107 phase 3 trial in June of 2017 and reductions in the Company's other research and development programs along with reductions in general and administrative expenses.